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Purpose: We aimed to list all tests used to assess cognitive change in patients with 
amyotrophic lateral sclerosis (ALS) and to provide a descriptive synthesis of the psycho-
metric properties of tests that were evaluated in a population of ALS patients.
Materials and Methods: The protocol is registered in PROSPERO (ID: CRD42017055603). 
We systematically search for literature in 11 databases. Full-text articles, in any language, with 
original research were included. All included articles were scrutinised by two independent 
authors. Disagreement was resolved by consensus. The framework of Lezak informed concep-
tualises of the tests identified. To evaluate methodological quality, we used the Consensus-based 
Standards for the Selection of Health Measurement Instruments (COSMIN). Data were synthe-
sised using criteria proposed by the Cochrane Back Review Group.
Results: Of 319 included articles, 46 articles reported information on the psychometric 
properties of cognitive tests used in patients with ALS. We found that the highest level of 
evidence was supported for the Reading the Mind in the Eye Test (RME), Addenbrooke’s 
Cognitive Evaluation (ACE) and Frontal Assessment Battery (FAB). Moderate level of 
evidence was found for the screening tests; Edinburgh Cognitive and Behavioural ALS 
Screen (ECAS) and the Montreal Cognitive Assessment (MoCA).
Conclusion: The screening test, ECAS and the social cognition test, RME, may have some 
advantages over other tests that have been used for assessing cognitive change in ALS 
patients. Recommendations of ALS-specific tests with sound psychometric properties are 
urgently needed.
Keywords: ALS, cognition, feasibility, reliability, test, validity
Introduction
Insight about the cognitive changes that might occur in amyotrophic lateral sclero-
sis (ALS) has increased during the last decades. Such changes are now recognised 
as one of the integral features that characterizes this multisystem disease.1 
Cognitive changes may influence ALS patient survival,2 caregiver burden,3 and 
affect decision-making processes regarding treatment.4 These findings stress the 
importance of accurately identifying those affected and detecting the extent of 
cognitive change.1,5 Early and repeated assessment may help healthcare profes-
sionals to better prepare families, enable individually tailored support, and provide 
timely opportunities for making essential decisions before impairment emerges.1,4
Recent studies show that the prevalence of cognitive changes in ALS varies 
between 30% and 62%.6,7 This wide range could be due to real differences in ALS 
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patient characteristics (ie disease stage) or different tests used 
to assess cognitive changes.8–10 During the past years, more 
focus has been directed on cognitive assessment and Strong 
et al have recently published revised diagnostic criteria for 
ALS-specific cognitive impairment.1 To better define the 
extent and nature of changes, the authors differentiate 
between brief assessments and screening in clinical settings, 
assessment for prognostic stratifications in clinical trials and 
assessment focusing on research. A diagnosis of ALS- 
specific cognitive change depends on evidence of changes 
in executive function, including social cognition and/or 
language.1 Although controversy, evidence of memory dys-
function in patients with ALS are increasing.1,7 Changes in 
these cognitive functions may occur separately or in combi-
nations with each other and should be assessed formally.1 As 
a minimum, Strong et al suggest assessment of Phonemic/ 
letter fluency early in the course of ALS, and that all patients 
undergo screening with the ALS Cognitive Behavioural 
Screen (ALS-CBS) or the Edinburgh Cognitive and 
Behavioural ALS Screen (ECAS).1,5,11 The necessity of 
further assessment may depend on whether changes in cog-
nition are registered and/or the setting in which an assess-
ment takes place.1 Moreover, the patient’s physical disability, 
risk of exhaustion and possible practice effect should be 
taken into account. Further, Strong et al provide a list of 
tests, sensitive to ALS and recommended for evaluation of 
executive function, language and memory. According to the 
authors, extended assessment should include neuropsychol-
ogists or speech and language pathologists to support admin-
istration and interpretation of cognitive profiles and may thus 
not be feasible.1 Despite these efforts, not all instruments/ 
tests are available everywhere yet and more effort and knowl-
edge are needed among both clinicians and researches. Better 
application of the Strong criteria,1 using tests covering a wide 
spectrum of cognitive symptoms may help to better under-
stand ALS-specific cognitive changes.9
To aid healthcare professionals to make informed 
choices as they select tests capable of detecting ALS- 
specific cognitive changes, this review has the following 
objectives: (i) to list cognitive tests applied in ALS- 
specific healthcare (Phase I); (ii) to provide a descriptive 
synthesis of the psychometric properties of tests that were 
evaluated in a population of ALS patients (Phase II).
Materials and Methods
To ensure transparent reporting, we report our systematic 
review according to the Preferred Reporting Items for 
Systematic Review and Meta-analysis (PRISMA).12
Protocol and Registration
The protocol was registered with the International 
Prospective Register of Systematic Reviews (PROSPERO) 
before any study procedures were undertaken. The protocol 
was last updated on February 12, 2020, at the PROSPERO 
site, available from: http://www.crd.york.ac.uk/PROSPERO/ 
display_record.php?ID=CRD42017055603.13
Eligibility, Exclusion, and Inclusion Criteria
Eligible for inclusion in this systematic review were 
research articles, published in full text and reporting on 
cognitive function in patients with ALS. Patients had to be 
diagnosed using recognised criteria common to ALS- 
specific healthcare.14–16 We excluded articles about studies 
that employed experimental cognitive paradigms and para-
digms used in combination with PET/CT/FMRI when 
focused on neuroanatomical questions of ALS. We also 
excluded articles reporting on children or animal. Included 
in Phase I were all relevant articles, regardless of the pub-
lication date, language they were written in and published. 
Of these results, we selected in Phase II, only those articles 
reporting on psychometric properties of cognitive tests that 
were evaluated in patients with ALS.
Information Sources
Systematic online searches were carried out in the 
Cochrane Library, McMaster+, Epistemonikos, Medline, 
Embase, SveMed+, CINAHL, AMED, OT seeker, PEDro 
and PsycINFO. We also checked the reference lists of 
systematic reviews we identified for additional relevant 
articles.
Search
A trained librarian carried out database searches. Our first 
search was carried out in February 2017 in order to identify 
the cognitive tests used in ALS-specific health care (Phase I). 
Search terms covered subject headings and free text words for 
the following three concepts: ALS/MND, cognition and spe-
cific cognitive domains known in ALS, and assessment tools. 
A second search was performed in December 2019 in order to 
find validating studies of cognitive tests used in patients with 
ALS (Phase II). In this second search we added a forth con-
cept; psychometrics, to the searches in the main medical 
databases (Medline, Embase, PsycINFO, CINAHL, 
Cochrane Library), according to the search strategy filters 
developed by the Hedges Team for detecting clinical predic-
tion studies.17,18 See Supplementary material 1 for the search 
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strings and the exact terms that we used for Medline and 
Embase in the first and the second search.
Study Selection and Data Collection 
Process
In Phase I, all references from the first search were screened. 
In Phase II in order to find validating studies, included refer-
ences from Phase I and new references from the second search 
were screened. Two of the authors independently screened all 
references and extracted the data. Consensus for inclusion was 
reached by discussion among the authors. For articles written 
in languages others than English, we consulted professional 
colleagues who are knowledgeable about health terminology 
in those languages. For eight articles, we contacted the authors 
for additional clarifying information.
Data Items
In Phase I, a neuropsychologist listed all the tests with 
sufficient supporting references used in the selected studies 
and classified them according to the cognitive domains they 
address; attention, concept formation and reasoning, con-
struction and motor performance, executive functioning, 
learning and memory, perception, social cognition, verbal 
functions and language skills. This procedure was mainly 
based on well-established work in the field of 
neuropsychology19,20 as well as on test manuals or aim (s) 
of the studies of the included articles. In this evaluation, we 
were aware that the classification could to some extent vary, 
depending on the perspective of the investigators. Batteries, 
rating scales, inventories and screening tests were cate-
gorised separately when all subtests were applied. Since 
several articles, however, reported on just a few subtests 
from the complete test battery, and names used seemed not 
always identical with the original ones, names of the bat-
teries were assigned to the above domain categories. When 
a complete battery was used, it was assigned separately.20
In Phase II, we extracted various characteristics of the 
included articles and published information on each identi-
fied test regarding psychometric properties. We were parti-
cularly interested in studies that evaluated the feasibility, 
internal consistency, reliability (test–retest reliability, inter- 
rater reliability), content validity, construct validity (struc-
tural validity and hypotheses testing), criterion validity and 
responsiveness of tests, as most of these evaluation para-
meters are specifically addressed in the Consensus-based 
Standards for the Selection of Health Status Measurement 
Instruments (COSMIN).21 In Table 1, definitions and 
explanations of the above-mentioned psychometric proper-
ties (except feasibility) are presented together with recom-
mendations of preferred statistical methods and minimum 
sample size to include in analyses.
Assessment of Study Quality (Risk of 
Bias)
In Phase II, we evaluated the risk of bias and methodolo-
gical quality of the studies in the included articles. We 
used the four steps of the COSMIN checklist.21 Only the 
standards corresponding to the psychometric property of 
interest were used and accompanied by specific explana-
tions and instructions given in the COSMIN checklist.21 
As feasibility is not part of the COSMIN checklist, we did 
not evaluate the methodological quality of studies that 
assessed the feasibility of the tests they used.
Level and Synthesis of Evidence
For tests identified in Phase II, we first calculated a quality 
score (excellent, good, fair, or poor) per measurement 
property, according to the scoring system developed by 
Terwee and colleagues.22 For each test of a study, psycho-
metric properties were assessed and were rated as adequate 
(+), not adequate (-) or unclear (?). A rating of 0 was given 
when no information was available in the article. We then 
synthesised individual ratings using the criteria proposed 
by the Cochrane Back Review Group, leading to cate-
gories of strong evidence, moderate evidence, limited evi-
dence, conflicting or unknown evidence.23
Ethical
Ethical approval and consent to participate are not applic-
able for this systematic review and analysis since no 
research subjects were recruited. This study adheres to 
the principles of the Declaration of Helsinki.24
Results
In Phase I for identifying cognitive tests, we included 319 
articles. The flow of information through Phase I of the 
systematic review is presented in Figure 1. Of these 319 
articles identified in our first search in 2017, 35 articles 
reported information on the psychometric properties of 
cognitive tests used in patients with ALS. In our second 
search conducted in 2019, we identified 11 new references 
reporting information on the psychometric properties of 
cognitive tests used in patients with ALS. A total of 46 
articles were therefore included in Phase II of our 
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Table 1 List of the Reported Psychometric Properties in Phase II – Definitions, Explanations and Recommendations of Preferred 
Statistical Method and Minimum Sample Size Included in Analyses
Psychometric Property – 
Definition and Explanations21
Preferred Statistical Method21 Sample 
Size21,22
Internal consistency:
Internal consistency measures the degree of -Cronbach’s alpha 50
interrelatedness among items. Internal consistency is only relevant when items form a 
reflective model, meaning all items are a manifestation of the same construct.
-Goodness of fit statistics 100-500
Assessment of the unidimensionality of the test is a prerequisite for internal consistency 
statistics to be evaluated objectively.
-Factor analysis or item response 
theory analysis
100-500
-Internal consistency coefficient for 
each (unidimensional) (sub)scale 
separately.
50
Reliability:
Reliability is the degree to which a test is free from measurement error. -ICC 
-Cohen’s kappa or weighted kappa 
depending on the scale used.
50
-Test-retest reliability refers to the robustness of the measurement error related to different 
testing times.
-Interrater reliability refers to the robustness of the measure-error related to different 
scorers. For evaluation of inter-rater reliability, the raters need to be independent.
Content validity (including face validity)
Content validity represent the degree to which the content of a test adequately reflect the 
construct to be measured. Content validity of a test is determined by asking patients for 
patient-reported tests or experts within the field of interest to judge the relevance and 
comprehensiveness of a test’s items. Evaluation of face validity is subjective; therefore, no 
standard exists.
Construct validity
Construct validity represent the degree to which the scores of the test are consistent with 
hypotheses based on the assumption that the test validly measures the construct to be 
measured.
-The structural validity aspect of construct validity refers to the degree to which the score of 
a test is an adequate reflection of the dimensionality of the construct to be measured. It is 
only relevant for tests that are based on a reflective model.
-Factor analysis 100
-The hypothesis testing aspect of construct validity concerns the relationships to scores of 
other instruments. It is recommended to formulate a priori hypotheses, to specify the 
expected direction (positive or negative) of correlations one expects, or to quantify the range 
of expected differences between groups or scores. It is important that the comparator test is 
clearly described and has adequate measurement properties in order to interpret 
correlations properly.
-Correlations 50
Criterion validity
Criterion validity refers to the degree to which the scores of a test are an adequate reflection 
of a ‘gold standard’ (an external criterion of the phenomenon being measured). For health- 
related patient reported outcome measures, the only possibility is to compare a shortened 
version of a test to the original long version.
-Correlations or the area under the 
ROC. 
-Sensitivity and specificity for 
dichotomous scores
50
(Continued)
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systematic review. See Figure 2 for flow of information 
through Phase II of the systematic review.
Phase I: Cognitive Tests Identified for Use 
in ALS-Specific Healthcare
Table 2 lists the most frequently reported; cognitive tests 
classified into eight cognitive domains, test batteries, and 
rating scales evaluated in the included articles. The total 
number of tests referenced within each cognitive domain 
and the total number of times a test is referenced are shown.
A complete list of all cognitive tests identified in Phase 
I are presented in Supplementary material 2. We observed 
that for some tests, several different versions were used, 
which indicates that the tests were in the process of being 
developed or had been revised (eg the Wechsler Adult 
Intelligence Scale), or that the tests were modified or 
adapted specifically for use in patients with ALS.
Table 1 (Continued). 
Psychometric Property – 
Definition and Explanations21
Preferred Statistical Method21 Sample 
Size21,22
Responsiveness
Responsiveness is the ability of a test to detect change over time in the construct being 
measured. When evaluating responsiveness, at a minimum, at least some of the patients 
should display changed performance (eg, improvement or decrement). Therefore, it is 
important to describe precisely what occurs during the follow-up. Responsiveness may be 
evaluated by hypotheses testing or comparison to a ‘gold standard’.
-Hypotheses testing: Correlations 
-Comparison to a gold standard: 
Correlations or the area under the 
ROC. 
-Sensitivity and specificity for 
dichotomous scores
50
Abbreviations: eg, for example; ICC, intraclass correlation coefficient; ROC, receiver operating characteristic.
Figure 1 Flow of information through Phase I of the systematic review: Identifying cognitive tests. 
Notes: Adapted from Liberati A, Altman D, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care 
interventions: explanation and elaboration. J Clin Epidemiol. 2009;62:10.  Creative Commons license and disclaimer available from: http://creativecommons.org/licenses/by/4. 
0/legalcode.12 
Abbreviation: ALS, amyotrophic lateral sclerosis.
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Phase II: Cognitive Tests That Were 
Evaluated in Patients with ALS
Table 3 summarises the characteristics of articles and 
studies reported therein that were included in Phase II of 
this review. All of the included studies reporting on feasi-
bility of tests, focused on the suitability of specific tests for 
use in patients with motor and speech impairment. The 
authors of those studies indicated that the Edinburgh 
Cognitive and Behavioural ALS screen (ECAS) might be 
more suitable for patients with ALS than the Frontal 
Assessment Battery (FAB) and the Montreal Cognitive 
Assessment (MoCA) screening test. Table 4 lists cognitive 
tests evaluated in patients with ALS identified in the first 
(2017) and second search (2019) of the review, and exam-
ined in Phase II according to their cognitive domain clas-
sification. Available in Table 4 is also information in 
which country each test has been validated.
Phase II: Assessment of Study Quality
Assessment of the methodological quality of included 
studies using the COSMIN checklist21 was for each 
psychometric property of interest (see Table 1 for defini-
tions and explanations):
Internal Consistency
None of the nine studies evaluating internal consistency 
explicitly described whether the tests used were based on 
a reflective or formative model. Nonetheless, all of the 
nine studies calculated Cronbach’s alpha or Item response 
theory (IRT), methods that are both adequate parameters 
of internal consistency. Four studies assessed the unidi-
mensionality of the test they used. Of these four studies, 
two conducted the unidimensional subtest separately, and 
all four had a sample size of greater than 50.
Reliability
None of the five studies that assessed reliability evaluated 
test–retest reliability. For evaluation of inter-rater reliabil-
ity, the raters were independent in four studies. Three 
studies used intraclass correlation coefficient, a preferred 
statistical measure of reliability. Two studies used 
Pearson’s correlation, which does not take systematic 
error into account. Two studies had a sample size of less 
than 50 participants.
Figure 2 Flow of information through Phase II of the systematic review: Evaluating psychometric properties. 
Notes: Adapted from Liberati A, Altman D, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care 
interventions: explanation and elaboration. J Clin Epidemiol. 2009;62:10.  Creative Commons license and disclaimer available from: http://creativecommons.org/licenses/by/4. 
0/legalcode.12 
Abbreviation: ALS, amyotrophic lateral sclerosis.
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Content Validity
One study assessed the content validity of the test they 
used; however, they did not provide a detailed description 
of how this was done.
Construct Validity – Structural Validity
None of the four studies evaluating structural validity expli-
citly described whether the tests they used were based on 
a reflective or formative model. Three studies used IRT 
Table 2 List of the Most Frequently Reported Cognitive Tests, Test Batteries and Scales Used in Patients with 
Amyotrophic Lateral Sclerosis (ALS) in 319 Articles Identified in Phase I
Cognitive Domains and Tests (Total Number of Tests Identified per Category)a Number of Articlesb
Cognitive domain, followed by 2 most-frequently used testsc
Attention, orientation and working memory (n=34)
Digit Span backward 89
Stroop Test/Color- Word Interference Test 78
Concept formation and reasoning (n=15)
Card sorting tests 77
Raven’s Coloured Progressive Matrices 52
Construction and motor performance (n=12)
Block Design 17
Complex Figure Test (copy) 9
Executive functioning (n=12)
Phonemic fluency tests 148
Category fluency tests 99
Learning and memory (n=37)
Complex Figure Test (recall) 43
Rey Auditory- Verbal Learning Test 41
Perception (n=14)
Benton Judgement of Line Orientation 23
Visual Object and Space Perception Battery 16
Social cognition (n=12)
Reading the Mind in the Eyes Test 10
Judgement of Preference Test 4
Verbal function and language skills (n=42)
Boston Naming Test 52
North American Adult Reading Test 34
Other kind of batteries or inventories, followed by 2 most-frequently used testsc
Test batteries (n=13)
Wechsler Adult Intelligence Scale 12
Mental Deterioration Battery 2
Rating scales, inventories and screening tests (n=32)
Mini-Mental State Examination 134
Frontal Assessment Battery 44
Notes: aCognitive tests are categorised according to the cognitive domain they assess, whereas the other kinds are categorised according to type 
of test (eg, scale, battery, etc.), as indicated. bA given article could report on more than one test. cSee Supplemental material 2 for the complete list 
of all reported tests.
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methods and followed the recommendation of checking the 
dimensionality of the items. One study that relied on classical 
test theory did not use factor analysis for this check, which is 
the preferred statistical method to determine the structure of 
the instrument.
Construct Validity – Hypothesis Testing
Of 28 studies evaluating hypothesis testing, 26 studies 
formulated a priori hypotheses. Specification of expected 
direction (positive or negative) of correlations one 
expected, or quantification of the range of expected differ-
ences between groups or scores were lacking completely 
or described only vaguely in 23 studies. Of the 14 studies 
that used hypothesis testing to investigate the convergent 
validity of tests, all 14 studies provided references for the 
comparator test; however, eight of these studies lacked 
information about measurement properties. In 27 studies, 
correlations were used. In seven studies, the sample size 
was inadequate.
Criterion Validity
In 24 of 29 studies evaluating criterion validity, we found 
that the authors compared the scores of the new test to 
a widely used one, not the original longer version. Statistic 
methods like correlation, receiver operating characteristics 
and sensitivity/specificity were used in all 24 studies. The 
sample size were inadequate in eight studies.
Responsiveness
All the three studies evaluating responsiveness tested the 
subjects at least two times during the assessment period 
and reported the time interval between measurements. 
Precise descriptions of what occurs during the follow-up 
were not adequately described in any of the included 
studies. To evaluate responsiveness, all three included 
studies tested a specific hypothesis. All three studies for-
mulated hypotheses a priori, but the hypotheses were for-
mulated only vaguely. Two studies reported p-values for 
the hypothesis testing they did, even if this should be 
avoided since it is not relevant to examine whether corre-
lations statistically differ from zero.70 The sample size in 
the analyses were too small in all the included studies.
Phase II – Synthesis of Evidence
The results from the synthesis of the evidence on the 
quality of the test psychometrics in Phase II of this review 
are presented in Table 5.
We found that the highest level of evidence was 
supported for the screening tests; Addenbrooke’s 
Cognitive Evaluation (ACE) and Frontal Assessment 
Battery (FAB), and the Reading the Mind in the Eye 
Test (RME), a test of social cognition. We found support 
for a moderate level of evidence for the ECAS and the 
MoCA screening tests and the Awareness of Social 
Inference Test, another test of social cognition. It should 
be noted that when evaluating the quality of screening 
tools, only the ECAS has alternative versions limiting 
practice effects. Moreover, it is available in several 
languages. Of all the included articles in Phase II, we 
observed that the greatest number of psychometric prop-
erties of interest was evaluated for the ACE and the 
ECAS. The Mini-Mental State Examination (MMSE) 
showed inconsistent levels of evidence.
Table 3 Characteristics of Articles Included in Phase II
Study Characteristics Values
Articles, number 46
Publication year, range 1985-2019
ALS-sample size per study, range 5-274
Mean age (year) of ALS patients, range 50.7 – 68.5
Recruitment setting, number of articles
Hospital or clinical 40
Register data 2
Others 4
Continent, number of articles
America 14
Asia 6
Europe 22
Oceania 4
Study design, number of articles
Cross sectional 38
Longitudinal 8
Cohort study 3
Case-control 19
Diagnostic 22
Combination of designs 2
Psychometrics, number of articles
Internal consistency 9
Reliability 5
Content validity 1
Construct validity – structural validity 4
Construct validity - hypothesis testing 28
Criterion validity 29
Responsiveness 3
Feasibility 5
Abbreviation: ALS, amyotrophic lateral sclerosis.
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Discussion
In this review, we had two aims: (i) to compile 
a comprehensive list of all cognitive tests used in ALS- 
specific healthcare and (ii) to provide a descriptive synth-
esis of the psychometric properties of tests validated in 
patients with ALS.
Our literature search and analyses indicated that a large 
number of tests are being used in ALS-specific healthcare. 
Of these tests, however, only a fraction have been evalu-
ated for use within a population of ALS patients. This may 
lead to different conclusions about a patient`s cognitive 
functioning.22 Although commonly used, some tests, 
Table 4 List of Cognitive Tests Evaluated in an ALS Population, Identified in the First and Second Search (2017 and 2019) of the 
Review and Examined in Phase II, Classified into Cognitive Domains
Test Country of Validation 
(Alphabetical Order)
Reference 
Number
Executive functioning
Category fluency tests Italy 25
Phonemic fluency tests Italy, Scotland 25,26
Learning and memory
Prospective memory test China 27
Social cognition
Awareness of Social Inference Test Australia 28
Ekman 60 Faces Test England 29
Reading the Mind in the Eyes Test Ireland 30
Screening tests
Addenbrooke’s Cognitive Examination Australia, Canada, China, Greece, Japan 31–36
ALS Brief Cognitive Assessment United States of America 37
ALS Cognitive Behavioural Screen Brazil, Italy, Spain, United States of America 38–42
Edinburgh Cognitive and Behavioural ALS Screen China, Czech Republic, Germany, Greece, 
Ireland, Scotland, Spain, Switzerland
5,35,43-53
Frontal Assessment Battery Australia, Canada, Italy, Japan, Korea, United 
States of America
25,36,54-58
Mini-Mental State Examination China, Italy, United States of America 25,34,37
Montreal Cognitive Assessment Canada, Japan 55,58
Penn State Brief Exam of Frontal and Temporal Dysfunction Syndromes United States of America 59
University of California San Francisco Screening Battery United States of America 60,61
Test batteriesa
ALS-Computerized Frontal Battery Canada 62
Battery I: Frontal Behavioral Inventory, Phonemic fluency test, Beck Depression 
Inventory
United States of America 63
Battery II: Addenbrooke’s Cognitive Examination-Revised, Digit Span-backword, 
Hayling Test, Iowa Gambling Test, Ekman 60 Faces-modified, Cambridge Behavioural 
Inventory-Revised
Australia 64
Battery III: ALS Cognitive Behavioural Screen, Phonemic fluency test, Semantic 
fluency test, Boston Naming Test-short version, Comprehension of Instructions, 
Peabody Picture Vocabulary Test-Revised
Greece 65
Battery IV: Token Test-modified, Graded Naming Test, British Picture Vocabulary 
Scale-II, Test for the Reception of Grammar, Pyramids and Palm Trees Test, Kissing 
and Dancing Test, Cookie Theft Picture
England 66
Battery V: Frontal Behavioural Inventory-Modified, Mini-Mental State Examination, 
Rey Auditory- Verbal Learning Test, Controlled Oral Word Fluency Test
United States of America 67
Communicative Participation Item Bank United States of America 68
Mental Deterioration Battery Italy 69
Notes: aBatteries I–V were developed specifically for use in patients with ALS. 
Abbreviation: ALS, amyotrophic lateral sclerosis.
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especially the MMSE, have produced conflicting evidence 
when it comes to assessing ALS-specific cognitive 
changes.25,34,56,67
To date, of the tests used to evaluate cognitive changes 
in ALS, none fulfils all of the essential measurement 
properties stipulated by the COSMIN checklist.21 We 
did, however, observe acceptable measurement properties 
for four screening tests; the ACE, FAB, ECAS and 
MoCA. Feasibility studies, however, showed that the 
ECAS might be more suitable, and hence preferable, for 
screening cognitive function in ALS patients compared to 
the FAB and MoCA, a finding that is in line with that of 
another systematic review.71 While several screening tests 
have been developed to detect cognitive changes, the 
Table 5 Levels of Evidence: Quality of Psychometric Properties and Feasibility of Tests in Articles Identified During Phase II
Test Internal 
Consistency
Reliability Content 
Validity
Structural 
Validity
Hypothesis 
Testing
Criterion 
Validity
Responsiveness Feasibility
Executive
Category fluency tests ?
Phonemic fluency tests ? ?
Learning memory
Prospective memory test ?
Social cognition
Awareness of Social Inference 
Test
++
Ekman 60 Faces Test ?
Reading the Mind in the Eyes Test +++ +++
Screening test
Addenbrooke’s Cognitive 
Examination
? ? +++ ? + x
ALS Brief Cognitive Assessment ?
ALS Cognitive Behavioural 
Screen
? x
Edinburgh Cognitive and 
Behavioural ALS Screen
? ? ++ ++ ? x
Frontal Assessment Battery +++ ? + x
Mini-Mental State Examination +/-
Montreal Cognitive Assessment ++ ? x
Penn State Brief Exam of Frontal 
and Temporal Dysfunction 
Syndromes
University of California San 
Francisco Screening Battery
? + ?
Test batteries a
ALS-Computerized Frontal 
Battery
?
Battery I ? x
Battery II ? ?
Battery III ?
Battery IV ? +
Battery V ?
Communicative Participation 
Item Bank
+ ? ?
Mental Deterioration Battery +
Notes: +++ or — = Strong evidence with consistent positive or negative results from multiple studies with good methodological quality or one study with excellent 
methodological quality. ++ or – = Moderate evidence with consistent positive or negative results from multiple studies with fair methodological quality or one study with 
good quality. + or - = Limited evidence with positive or negative results from a study with fair methodological quality. +/− = Conflicting evidence with conflicting results from 
individual studies. ? = Unknown level of evidence due to results from studies with poor methodological quality. x =Feasibility was evaluated. Gray-highlighted box indicate 
high to moderate level of evidence. aBatteries I–V were developed specifically for use in patients with ALS. 
Abbreviation: ALS, amyotrophic lateral sclerosis.
Taule et al                                                                                                                                                             Dovepress
submit your manuscript | www.dovepress.com                                                                                                                                                                                                                    
DovePress                                                                                                                                            
Patient Related Outcome Measures 2020:11 190
 
P
at
ie
nt
 R
el
at
ed
 O
ut
co
m
e 
M
ea
su
re
s 
do
w
nl
oa
de
d 
fr
om
 h
ttp
s:
//w
w
w
.d
ov
ep
re
ss
.c
om
/ b
y 
91
.1
26
.8
.1
62
 o
n 
06
-F
eb
-2
02
1
F
or
 p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
ECAS has been designed specifically to assess cognitive 
changes in patients with ALS.5 Strong et al recommend 
that either the ECAS or the ALS-CBS be administered to 
all patients.1 However, in our review, we found the psy-
chometric properties of the ALS-CBS poorly evaluated. 
Our analysis revealed that, of all the screening tests eval-
uated in the included studies, the psychometric properties 
of the ECAS and ACE were the most scrutinised. It 
should be noticed, however, that effort has been made to 
provide alternate versions of the ECAS.72 The challenge 
in recurrent testing is that the disease may sometimes 
deteriorate quickly. Therefore, the tests should be easy 
to perform, but not be easily remembered and learned at 
the same time. This enables recurrent testing which is 
desirable to follow the development of cognitive changes 
over time. This way, significant practice effects can be 
reduced if not eliminated. Moreover, translations in sev-
eral languages would allow international multicentre stu-
dies, which could increase knowledge and patient care.
Of two tests of social cognition evaluated in patients 
with ALS, we found that the highest level of evidence was 
supported for the RME. Although not specifically devel-
oped for use in patients with ALS, the RME accounts for 
potential physical disability as it can be conducted in 
either written or spoken.73 The RME is recommended by 
Strong et al for evaluation of the ability to read the emo-
tions of others, a social cognitive process most likely in 
patients with ALS who meet the criteria for frontotemporal 
dementia.1
Our data suggest that the ECAS may be preferred over 
other screening tests for validly and reliably screening 
cognitive change in patients with ALS and that the RME 
may be suitable for the extended assessment of social 
cognition. The advantage of ECAS is that it is an ALS- 
specific test and therefore may show changes that are 
characteristic for ALS. However, our data did not allow 
us to give clear recommendations on which specific tests 
to use for extended assessment of other cognitive changes 
that may occur in patients with ALS. Similar methodolo-
gical flaws recurring across the included studies preclude 
us from making such recommendations, and also prompt 
us to highlight the need for researchers and clinicians to 
pay particular attention to the methods applied in psycho-
metric studies. Hence, there is a great potential for improv-
ing the methodological quality of studies that aim to 
evaluate the measurement properties of a cognitive test 
used in ALS-specific healthcare.
Study Strengths and Limitations
The strengths of the current study lay in the rigorous quality 
assessment achieved by the use of the COSMIN checklist, 
a widely used and validated tool to assess the risk of bias in 
evaluating measurement properties of a test.21 Also, in 
combination with the COSMIN checklist, we used recom-
mended quality criteria21 to synthesise the level of 
evidence.22 Other strengths are that a trained librarian con-
ducted the literature search and that the searches were 
relatively comprehensive and exhaustive. However, we did 
not consult all databases, nor grey literature, a strategy that 
future reviews might consider.
This review did not take studies in healthy controls 
into account. A more accurate reflection of the psycho-
metric properties of each test would include studies with 
healthy controls. Therefore, the reliability and validity of 
some tests may be underestimated. The analyses demon-
strate that in particular, screening instruments have been 
evaluated so far, and more research is needed with 
regard to evaluate further cognitive/neuropsychological 
tests. Another limitation can be the inclusion of articles 
since 1985, since this may risk confusing the results as 
different versions of cognitive tests may have varying 
psychometric properties. We argue that our aim was to 
provide a comprehensive overview possibly also includ-
ing results from countries where not all tests/versions are 
available yet. Furthermore, the analyses in the present 
study are limited to the assessment of cognition as one 
aspect of behavior. We acknowledge the importance to 
investigate tests assessing emotional aspects of behavior 
as a future.
The quality of included studies was rated as fair to poor 
in many cases, which limits the conclusions we can draw. 
Available data did not allow us to conduct meta-analyse 
and we could not perform assessments of heterogeneity. 
Thus, at this point, we can only give guarded advice for 
tests that should be used in ALS-specific healthcare. We 
are aware that the presence of publication bias may have 
affected our results. Finally, some evaluator bias may have 
also affected our result, because three of the authors of this 
review are involved in the validation of the Norwegian 
version of the ECAS.74
Conclusions
To the best of our knowledge, this is the first study to 
systematically identify and evaluate tests that are used to 
measure the cognitive change in ALS and those tests that 
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have been validated in patients with ALS. The screening 
test, ECAS and the social cognition test, RME; may have 
some advantages over other tests that have been used for 
assessing cognitive change in ALS patients. Psychometric 
properties of tests that were evaluated in a population of 
ALS patients have mainly been examined in screening 
instruments. Thus, more research regarding the validation 
of comprehensive neuropsychological assessment seems 
appropriate to implement the recent ALS criteria.1
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